Breakthroughs in Non-Alcoholic Steatohepatitis Management Drives Potential for Better Treatment Outcomes

Topic Discussed : Breakthroughs in Non-Alcoholic Steatohepatitis Management

Speaker: Deepak Jayakumar

Key Takeaways:

1. Intercept Pharmaceuticals’ Ocaliva (Obitecholic acid) is on track to become the first-ever FDA-approved drug for the treatment of NASH. If approved, it’s only market concern could be its side-effect profile that includes itching. Currently, the clinical pipeline for NASH involves mostly small molecule drugs than biologics
2. Adaptive clinical trial designs are increasingly being adopted by clinical trial sponsors and collaborators. This type of trial ensures accelerated development through trial modification based on clinical outcome without compromise on validity and integrity of trial outcome
3. Organ-on-a-chip and 3D NASH assay models are also being increasingly used by pharmaceutical companies. This is due to the model’s ability to better mimic the biological integrity of the disease which can better predict the clinical translation

For further insights, please join us for future podcasts and become a member of Frost & Sullivan’s Leadership Council by emailing us at: digital@frost.com or click here to Contact Us.

Related Keywords: Frost & Sullivan, Non-alcoholic steatohepatitis, steatohepatitis, NASH, non-alcoholic fatty liver disease, Fatty liver disease, NAFLD, Liver-on-a-chip models, Liver preclinical assays, NASH animal models, NASH clinical trial candidates, Treatment for NASH

Website: www.frost.com

Hosted on Acast. See acast.com/privacy for more information.